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Early embryonic development is driven exclusively by maternal gene products 
deposited into the oocyte. Although critical in establishing early developmental 
programs, maternal gene functions have remained elusive due to a paucity of 
techniques for their systematic disruption and assessment. CRISPR-Cas13 systems 
have recently been employed to induce RNA degradation in yeast, plants and 
mammalian cell lines. However, no systematic study of the potential of Cas13 has been 
carried out in an animal system. Here, we show that CRISPR-Cas13d is an effective 
and precise system to deplete specific mRNA transcripts in zebrafish embryos. We 
demonstrate that both zygotically-expressed and maternally-provided transcripts are 
efficiently targeted, resulting in an 80% average decrease in transcript level and the 
recapitulation of well-known embryonic phenotypes. Moreover, we show that this 
system can be used in medaka, killifish and mouse embryos. Altogether our results 
demonstrate that CRISPR-Cas13d is an efficient knock-down platform to interrogate 
gene function in animal embryos. 
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Introduction 
The experimental dissection of gene function has been radically transformed with 
the advent of DNA engineering technologies such as TALEN and CRISPR-Cas9 
systems (Hsu et al., 2014). These tools allow researchers to link genotype to cellular 
phenotypes through the generation of permanent changes to the genome. 
Complementary ‘knock-down’ approaches such as RNA interference have also proven 
to be invaluable tools to interrogate gene function. However, in aquatic vertebrate 
organisms such as zebrafish (Danio rerio), other teleost fish and Xenopus (Chen et al., 
2017; Lund et al., 2011), attempts to establish efficient RNAi technologies have largely 
failed (Chen et al., 2017; Kelly and Hurlstone, 2011; Lund et al., 2011). In their place, 
morpholinos (MOs), and more recently, antisense oligonucleotides (ASOs), have been 
used to perturb RNA activity (Pauli et al., 2015; Stainier et al., 2017). While an ASO-
based approach has not been followed up since its implementation in zebrafish (Pauli et 
al., 2015), MOs have been widely implemented for over two decades. MOs are nucleic 
acid-analog antisense oligomers that disrupt RNA function/output by blocking translation 
or splicing (Stainier et al., 2017). However, the utility of MOs has recently been called 
into question due to observed toxicity and off-target effects (Gentsch et al., 2018; Joris 
et al., 2017; Kok et al., 2015; Lai et al., 2019; Robu et al., 2007; Schulte-Merker and 
Stainier, 2014). In several instances, discordant phenotypes have been observed 
between MO-treated animals and loss-of-function mutant animals and, more strikingly, 
additional phenotypes have been observed upon MO treatment in loss-of-function 
mutant backgrounds, indicating cellular effects unrelated to targeted RNA knock-down 
(Joris et al., 2017; Kok et al., 2015). More recently, studies have shown that some MOs 
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can trigger an innate immunity response, interferon-stimulated and cellular stress 
response gene up-regulation, and off-targeting through mis-splicing in zebrafish and 
Xenopus (Gentsch et al., 2018; Joris et al., 2017; Lai et al., 2019; Robu et al., 2007), 
reinforcing the need for established controls to ensure the fidelity of MO-induced 
phenotypes (Stainier et al., 2017). These concerns, as well as the high expense of 
morpholinos, tedious methods for validating efficacy and fidelity (i.e. assessment of 
protein output or ribosome occupancy) (Lee et al., 2013), and the inability to implement 
in a tissue-specific or temporal manner, have limited their use in systematic approaches 
to studying gene function in teleost and amphibian embryos.  
    RNA ‘knock-down’ approaches hold many advantages compared to DNA 
mutagenesis (e.g. Cas9). The ability to directly disrupt gene activity sidesteps the need 
for laborious multi-generation genotype screening to establish permanent genetic 
strains. Likewise, knock-down strategies allow for the study of in vivo maternal effects 
without the need for homozygous mutant mothers (Ciruna et al., 2002; Moreno-Mateos 
et al., 2015), which for many critically important genes are either unviable or infertile 
(Abrams and Mullins, 2009; Ciruna et al., 2002). Furthermore, by directly manipulating 
RNA activity in a relatively tunable manner, researchers can study how subtle changes 
in transcript levels impact biological processes. In fact, by reducing but not completely 
removing gene activity, researchers can uncover phenotypes that may otherwise remain 
hidden due to loss-of-function lethality (Smith et al., 2017). Finally, therapeutic 
approaches that target RNA rather than DNA can be advantageous in providing 
temporary but effective modifications without the prospect of permanent heritable 
changes (Cox et al., 2017).   
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 Cas13 is a class 2/type VI CRISPR-Cas RNA endonuclease, which has recently 
been employed to induce both the cleavage and subsequent degradation of RNA in 
fission yeast, plants and mammalian cell lines (Abudayyeh et al., 2017; Aman et al., 
2018; Cox et al., 2017; Jing et al., 2018; Konermann et al., 2018). This method has 
been shown to be more effective and specific than RNAi in mammalian cells 
(Abudayyeh et al., 2017; Cox et al., 2017; Konermann et al., 2018). However, to date, 
no systematic study of the potential of Cas13 has been carried out in an animal model 
system. Here, we show that CRISPR-RfxCas13d (CasRx), but not Psp/PguCas13b or 
LwaCas13a, is an effective and precise system to deplete specific mRNA transcripts in 
zebrafish embryos. We demonstrate that zygotically-expressed, as well as ectopic or 
maternally-provided transcripts are efficiently targeted, resulting in an average of more 
than 80% decrease in transcript levels and the recapitulation of well-known maternal 
and/or zygotic embryonic phenotypes. Importantly, through whole transcriptome 
sequencing, we observed highly specific knock-down. Finally, we successfully 
implement CRISPR-Cas13d system in other research organisms such as medaka 
(Oryzias latipes), killifish (Nothobranchius furzeri) and mouse (Mus musculus) embryos, 
demonstrating its applicability across a range of aquatic and terrestrial animal models. 
Our results establish CRISPR-Cas13d as an efficient and straight-forward method for 
the systematic, tractable, and unambiguous study of gene function in vivo during  
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Design 
Gene knock-down approaches such as RNA interference serve an invaluable 
role in elucidating gene function. However, in aquatic vertebrate organisms such as 
zebrafish and other teleost fish, RNA interference has failed to develop as an efficient 
and systematic tool. Instead, MOs have been used to disrupt gene function by blocking 
translation or preventing RNA splicing. However, MOs can induce nonspecific effects 
that are separate from target RNA perturbation(Gentsch et al., 2018; Joris et al., 2017; 
Lai et al., 2019; Robu et al., 2007). Further, researchers have found that MO-based 
phenotypes can differ form those obtained by genetic mutation (Kok et al., 2015). 
Although these differences may be explained, in part, by genetic compensation (El-
Brolosy et al., 2019; Ma et al., 2019; Rossi et al., 2015), the use of MOs requires 
several proper controls to ensure accuracy (Stainier et al., 2017).  Based on the 
limitations and caveats of current knockdown technologies in teleosts, we set out to 
develop and optimize a Cas13/CRSPR- based method to disrupt gene function.  We 
had two goals: to develop 1) a technique that could be used in a cost-efficient and 
systematic manner and 2) a viable approach to interrogate maternally-provided 
developmental programs in the early embryo. The study of early development in animal 
embryos, which is driven by thousands of mRNAs that are maternally provided (Lee et 
al., 2014), requires elaborate genetic schemes to remove maternal activity.  Herein, we 
find that, among various Cas13 variants tested, RfxCas13d efficiently disrupts maternal 
and zygotic gene function without embryonic toxicity, and with high specificity, in 
zebrafish embryos.  We successfully apply this approach to gene knockdown in 
medaka, killifish and mouse embryos. Therefore, CRISPR-RfxCas13d is a robust and 
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cost-effective technology to systematically disrupt gene function in vertebrates.  We 
envision the application of this method to the study of gene expression in a high-
throughput manner in the early embryo, as well as applied for use in tissue-specific 
manners.   
Results  
Optimization of RNA targeting by CRISPR-Cas13 in zebrafish embryos 
 To assess the potential toxic effects of different Cas13 proteins successfully used 
in mammalian cells (Abudayyeh et al., 2017; Cox et al., 2017; Konermann et al., 2018), 
we constructed expression vectors to generate mRNA encoding four different Cas13 
variants (RfxCas13d, PguCas13b, PspCas13b or LwaCas13a-GFP). The mRNA for 
each Cas13 variant was injected individually into one-cell stage zebrafish embryos 
(Figure 1A). Protein expression in vivo was confirmed for all Cas13 variants tested 
(Figure S1A) except LwaCas13a-GFP likely due to a low stability of LwaCas13 mRNA 
as reported in mammalian cells (Abudayyeh et al., 2017) (Figure S1B). While 
PguCas13b and PspCas13b negatively impacted embryonic development (Figures 1B 
and S1C), RfxCas13d displayed no toxic effects (up to 300 pg of mRNA per embryo; 
Figure S1D). Hence, we limited subsequent analyses of endogenous mRNA abrogation 
to RfxCas13d. First, to test whether Rfx-Cas13d could trigger the degradation of specific 
mRNAs in zebrafish embryos, we designed six guide RNAs (gRNAs) complementary to 
different sequences within the coding sequence (CDS) of the tbxta mRNA pooled into 2 
sets of gRNAs (Figures 1C, S1E and S1F). Notochord formation is compromised in 
tbxta loss-of-function mutant embryos resulting in a dorsalization phenotype (no-tail) 
(Halpern et al., 1993; Schulte-Merker et al., 1994). Co-injection of RfxCas13d mRNAs 
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with different sets of tbxta gRNAs (Figure 1C) recapitulated the no-tail phenotype at 30 
hours post injection (Figures 1D, 1E and S1G). Importantly, the no-tail phenotype was 
only observed when tbxta gRNAs and RfxCas13d mRNA were co-injected (i.e., no 
phenotype was observed when either gRNAs or RfxCas13d mRNA were injected singly) 
and its penetrance correlated with RfxCas13d dosage (Figure 1E). Further, co-injection 
of RfxCas13d mRNA with gRNAs targeting dnd1, a gene controlling an unrelated 
developmental process (germ cell development and survival) (Weidinger et al., 2003), 
did not lead to dorsalization (Figure 1F). In addition, the CRISPR-RfxCas13d system 
triggered tbxta mRNA degradation by at least 6 hours post injection (Figure 1G). While 
the addition of nuclear localization sites (NLS) increased RfxCas13 activity in 
mammalian cells(Konermann et al., 2018), we observed that incorporation of an NLS 
decreased phenotypic penetrance in zebrafish embryos (Figure S1H) (P < 3.4e-9, Chi-
Square). Finally, to confirm the specificity of the phenotype, we designed a new set of 
three gRNAs targeting the tbxta 3’UTR which also induced the no-tail phenotype (Figure 
1F). This phenotype was specifically rescued (P < 2.07e-3, Chi-Square) by injection of 
the cognate mRNA (lacking endogenous 3’UTR), but not by injection of mRNA encoding 
GFP (P < 0.02, Chi-Square) or the antisense tbxta coding region (P < 0.29, Chi-Square) 
(Figures 1F and S1I). Together, these results establish CRISPR-RfxCas13d as an 
efficient tool to trigger endogenous mRNA knock-down during zebrafish embryogenesis. 
 
CRISPR-RfxCas13d triggers effective and precise reporter mRNA depletion in 
zebrafish embryos 
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To further assess the efficacy of the CRISPR-RfxCas13d system to impair mRNA 
activity, two sets of three gRNAs each, specific to the CDS of either Red Fluorescent 
Protein (RFP) or Nano-luciferase mRNAs were individually injected along with 
RfxCas13d mRNA into zebrafish embryos (Figures 2A and B). Reporter activity (Figures 
2C and D), as well as the respective mRNA levels (Figures 2 E and F), were 
significantly reduced in zebrafish embryos after 6 hours post injection when compared 
to embryos injected with control conditions (Figures 2C-F). Moreover, RfxCas13d 
mRNA coupled with individual gRNAs was sufficient to reduce RFP fluorescence 
intensity (Figure S2A). Notably, fluorescence intensity and activity of two control 
mRNAs, Green Fluorescent Protein (GFP) and Firefly, respectively, did not change 
appreciably in all conditions tested (Figures 2C , S2A and S2B), and only targeted 
mRNAs (RFP and Nano-luciferase) displayed reduced mRNA levels (Figures 2C-F and 
S2A), suggesting that the CRISPR-RfxCas13d system is specific.  
To address whether the CRISPR-RfxCas13d system could be used to target 
maternally deposited mRNAs, zebrafish embryos derived from a transgenic mother that 
expresses rfp at very high levels (i.e. among the top 100 most highly expressed 
maternal mRNAs) were injected with RfxCas13d mRNA plus three gRNAs targeting rfp 
(Figure 2G). Fluorescence intensity was visibly reduced after 24 hours post injection 
when compared to embryos injected with RfxCas13d mRNA or gRNAs alone, or by co-
injection of RfxCas13d with unrelated gRNAs (Figure 2H). Interestingly, the reduced 
level of RFP persisted for the first 3.5 days and partially recovered after 5 days (Figure 
S2C and S2D, respectively). Furthermore, rfp mRNA levels displayed an approximately 
4.4. fold reduction (77.3 %; P adjusted < 7.64e-6) compared to embryos injected with 
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RfxCas13d mRNA alone after 6 hours post injection by RNA-seq (Figure 2I) and q-RT-
PCR (Figure S2E). Moreover, RNA-seq analysis displayed a similar expression RNA 
level in zebrafish embryos injected with RfxCas13d mRNA alone or uninjected embryos 
(Figures 2I and S2F). Interestingly, within the co-injected embryos with RfxCas13d 
mRNA and gRNAs targeting rfp mRNA, RFP was the most down-regulated at the 
mRNA level (Figures 2I and S2F). Together, these results indicate that the CRISPR-
RfxCas13d system can functionally disrupt the activity of maternally-provided mRNAs in 
a specific manner during early development in zebrafish embryos with minimal off-target 
effects detected.  
 
CRISPR-RfxCas13d system efficiently depletes endogenous maternally provided 
and zygotically-expressed mRNAs in zebrafish embryos 
 We next tested our optimized CRISPR/RfxCas13d method on endogenous 
mRNAs with known roles in embryonic development. We chose three genes whose 
loss-of-function phenotypes had been previously established. First, we targeted dnd1 
mRNA, whose impairment abolishes primordial germ cell migration and survival 
(Weidinger et al., 2003). Embryos co-injected with RfxCas13d mRNA and 3 gRNAs 
targeting dnd1 were devoid of detectable germ cells, as indicated by loss of germ cell-
specific GFP expression (from co-injection with GFP-nanos 3’UTR marking germ cells) 
(Figure 3A), recapitulating the phenotype observed in embryos injected with a 
morpholino targeting dnd1 mRNA (Ciruna et al., 2002). In contrast, germ cells were not 
visibly affected by injection of RfxCas13d mRNA alone or in conjunction with gRNAs 
targeting an unrelated mRNA (Figure 3A). RNA-seq and qPCR analysis confirmed 
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specific reduction (8-fold change -87.5%-, P adjusted < 2.76e-6, RNAseq) of dnd1 
mRNA levels (Figures 3B and S3A). Notably, dnd1 mRNA was the most differentially 
expressed mRNA (at 6 hpi) when compared to embryos injected with RfxCas13d mRNA 
alone (Figures 3B and S3B). Together, these results demonstrate the robustness and 
specificity of dnd1 knock-down by CRISPR-RfxCas13d system, which recapitulates the 
loss of germ cells.  
Second, to test whether the CRISPR-RfxCas13d system could be used to reduce 
mRNA levels of later developmental genes, we designed three gRNAs targeting the 
tyrosinase (tyr) mRNA involved in pigmentation whose transcription starts at 16-17 
hours post fertilization (Camp and Lardelli, 2001). Embryos injected with tyr gRNAs and 
RfxCas13d mRNA displayed loss of both eye and body pigmentation when compared to 
embryos injected with either Rfx-Cas13d mRNA or tyr gRNAs alone (Figures 3C and 
S3C). These results suggest that CRISPR-RfxCas13d can be used to knock-down 
zygotically-derived mRNAs transcribed later during embryogenesis.  
Third, nanog, is a potent transcription factor involved in the activation of the 
zygotic gene expression in zebrafish (Gagnon et al., 2018; Lee et al., 2013; Veil et al., 
2018) and injection of morpholinos targeting nanog mRNA or maternal and zygotic loss-
of-function mutants induce severe gastrulation deficiencies and epiboly failure in 
zebrafish embryos (Lee et al., 2013; Veil et al., 2018). In a similar manner, embryos 
injected with RfxCas13d mRNA and three gRNAs targeting nanog mRNA displayed a 
significant reduction in nanog mRNA levels at 6 hours post injection (6-fold change, 
84%, P adjusted < 3.536e-9, RNAseq) (Figures 3E, S3F and S3G) with similar 
consequences to gastrulation (Figures 3D, S3D and S3E) and downstream gene 
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expression (nanog targets; Figure 3E). For example, mRNAs downregulated in embryos 
injected with RfxCas13d mRNA plus nanog gRNAs (139 mRNAs, P < 1e04, fold 
change> 2) were also downregulated in nanog morpholino-treated embryos (Lee et al., 
2013) (P < 4.4e-11, Wilcoxon rank sum test) (Figures S3G and S3H). Conversely, 
mRNAs that displayed a greater than 4-fold reduction in nanog MO-treated embryos 
were also repressed after co-injection of RfxCas13d mRNA and nanog gRNAs (P < 
1.7e-05, Wilcoxon rank sum test) (Figure 3E). Given the strong correspondence 
between MO and CRISPR-RfxCas13d methods, affected mRNAs are likely true targets 
of nanog (both direct and indirect). Altogether, our data show that the CRISPR-
RfxCas13d system is a precise tool to impair maternal and zygotic gene activity in 
zebrafish embryos reducing in approximately 80% the level of mRNA (Figure S3I).  
 
CRISPR-RfxCas13d as RNA targeting tool in different animal models 
 To determine how the CRISPR-RfxCas13d system performs in other animal 
models, we first assessed its activity in medaka, another fish model for which RNAi is 
ineffective (Chen et al., 2017). Loss-of-function mutations in the rx3 (rax) gene result in 
arrested eye development (Loosli et al., 2001). Co-injection of RfxCas13d mRNA plus 
three gRNAs targeting the rx3 mRNA into one-cell stage medaka embryos resulted in 
rx3 mRNA depletion (Figure S4A) (uninjected or RfxCas13d mRNA alone vs RfxCas13d 
mRNA and gRX3, P value=0.01 and 0.01, respectively; One-way ANOVA), and severe 
microphtalmia and/or anophthalmia, which were not observed with injection of 
RfxCas13d mRNA alone (Figures 4A , S4B and C) (P < 2.7e-12, Chi-Square). Next, we 
assessed the ability of RfxCas13d to disrupt reporter mRNA activity in the killifish 
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(Nothobranchius furzeri), a research organism used to study aging and regeneration. 
We introduced mRNAs encoding gfp, rfp, RfxCas13d, as well as three gRNAs targeting 
rfp. We observed between 70 to 95% reduction in RFP mRNA level and fluorescence 
intensity 14 hours post injection when compared to control embryos (i.e. RfxCas13d 
mRNA or gRNAs alone; Figures 4B, S4D and S4E). Together, these results suggest 
that the CRISPR-RfxCas13d system can be widely applied across several animal 
species, including those historically recalcitrant to RNAi-based knock-down 
methodologies (e.g. zebrafish, medaka and killifish) (Chen et al., 2017).   
Although CRISPR-Cas13 has been shown to be effective in cultured mammalian 
cells, its efficacy has, to date, not been determined in a mammal in vivo. Therefore, we 
next assessed potential toxic effects of increasing concentrations of RfxCas13d mRNA 
in one-cell stage mouse embryos. We find that up to 1-2 pl of 25 ng/ul of RfxCas13d 
mRNA is tolerated with no deleterious effects (Figures S4F and S4G). Importantly, we 
observed lower RFP fluorescence intensity at 2-cell stage when RfxCas13 mRNA was 
co-injected with rfp mRNA and respective gRNAs, compared to mouse embryos 
injected with either RfxCas13 mRNA or rfp gRNAs alone, as well as in the presence of 
RfxCas13 mRNA plus three unrelated gRNAs targeting the Danio rerio Tyr gene (Figure 
4C). To assess the effects on endogenous gene activity, we designed gRNAs targeting 
ubtf and emg1 mRNAs. In both cases, introduction of RfxCas13d mRNA plus respective 
pools of gRNAs resulted in developmental arrest (P=1e-03 and P < 3.5e-05, 
respectively compared to RfxCas13d; Chi-Square) (Figure 4D), similar to previously 
observed phenotypes in loss-of-function mutant embryos (Hamdane et al., 2014; Wu et 
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al., 2010). Together, these results suggest that the CRISPR-RfxCas13d system can 
serve as an effective additional knock-down tool in mice. 
 
Discussion 
The ability to experimentally modulate gene activity is critical for understanding 
biological function. In this study, we show that the CRISPR-RfxCas13d system provides 
a robust, highly efficient, specific and straight-forward method to disrupt mRNA function 
in a wide variety of embryonic animal models.  
A CRISPR-Cas-based system for perturbing RNA function has several 
advantages. Foremost, as shown here, Cas13-mediated knock-down can be applied to 
teleost fish models in which current RNAi methodologies remain ineffective (Chen et al., 
2017; Kelly and Hurlstone, 2011). The CRISPR-Cas13 system does not burden 
endogenous cellular machinery. This is of particular concern in aquatic vertebrates such 
as Xenopus, where the sequestration of Argonaute proteins by exogenous RNAi is 
thought to compromise endogenous microRNA function (Kelly and Hurlstone, 2011; 
Lund et al., 2011). Another advantage lies in the ease, flexibility, and cost-effectiveness 
of this approach. Researchers can generate gRNAs through conventional in vitro 
transcription reactions with PCR-generated templates, allowing for both individual and 
pools of gRNAs. Since RfxCas13 does not have nucleotide sequence restrictions or 
protospacer flanking site (PFS) requirements in eukaryotic cells (Abudayyeh et al., 
2017; Cox et al., 2017; Konermann et al., 2018), any sequence can be potentially 
targeted, including untranslated regions as well as long non-coding RNAs. Since mRNA 
levels are directly impacted by targeted degradation (in contrast to most MO-based 
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strategies), validation can be easily performed via Northern blot analysis, quantitative 
RT-PCR, or RNA-seq. Moreover, the potential off-target effects can also be assessed 
by RNA-seq.  In addition, we have found that RfxCas13d performs better than a 
RfxCas13d variant with two nuclear localization signals (NLS; on N- and C-termini) in 
zebrafish embryos. However, we cannot rule out the possibility that NLS-containing 
versions will be more effective in other model animal systems or under ubiquitous 
expression of both RfxCas13d and gRNAs, as has been shown in mammalian cells 
(Konermann et al., 2018). 
Remarkably, our results indicate that injection of RfxCas13d mRNA plus gRNAs 
is sufficient to rapidly target maternally-provided nanog transcripts and recapitulates 
MO-induced molecular and developmental phenotypes, bypassing the need for using 
Cas13d purified protein. Given the ease and reduced cost of this approach, we envision 
the application of this tool toward large-scale screening of maternal factors (both coding 
and noncoding) involved in early development in different aquatic vertebrate systems. 
However, it is important to note that in vitro pre-assembly of the Cas13d protein 
complex may more rapidly reduce maternal mRNA activity and therefore, increase the 
penetrance of maternal phenotypes. 
  Nonetheless, we envision a range of potential future applications. Transgenic 
lines expressing RfxCas13d, either ubiquitously, or in an inducible, tissue or cell-specific 
manner, can be applied to the study of genes involved later in development, as well as 
for targeting genes whose disruption results in early lethality or deleterious effects of 
ambiguous origins. In sum, we have found that CRISPR-RfxCas13d system is 
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adaptable and effective in a broad spectrum of animal models, and as such, will be an 
invaluable tool for unraveling gene function in a large variety of developmental contexts. 
Limitations 
We have shown that CRISPR-RfxCas13d can disrupt maternal programs by 
targeting maternal mRNAs. However, as with other knock-down techniques in teleost 
embryos, this approach cannot target maternally provided protein.  Further, although we 
find that injection of rfxCas13d mRNA is efficient in disrupting early maternal gene 
activity, (e.g.nanog), we posit that injection of purified RfxCas13d protein or maternal 
expression of RfxCas13d protein (via transgenic expression) could potentially lead to 
faster activation and thereby increase the penetrance of the maternal phenotype. 
Finally, it has recently been shown that genetic compensation can be triggered by RNA 
degradation (El-Brolosy et al., 2019; Ma et al., 2019).  Further work should examine 
whether, in some cases, Cas13d-mediated cleavage of target mRNAs can activate the 
transcriptional adaptation response.    
 
Methods  
Guide RNA and mRNA generation 
Guide RNA (gRNA) design was based on CRISPR-Cas13 targeting data in 
mammalian cell culture in which there was not any significant protospacer flanking site 
preference (PFS) reported and gRNA activity partially correlated with target accessibility 
(Abudayyeh et al., 2017; Konermann et al., 2018). Thus, mRNA targets were analysed 
in silico using RNAfold software (http://rna.tbi.univie.ac.at//cgi-
bin/RNAWebSuite/RNAfold.cgi) (Lorenz et al., 2011) and protospacers of 22 
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nucleotides (target sequences) with high accessibility (low base-pairing probability from 
minimum free energy predictions) within the target mRNAs were selected to generate 
gRNAs. DNA template to generate gRNA was generated by fill-in PCR (Figures S1E 
and S1F). A gRNA universal primer (Table S1) containing the T7 promoter (5′-
TAATACGACTCACTATA-3) and the processed direct repeat for RfxCas13d gRNAs (30 
nt) preceded by 5′GG was used in combination with a specific oligo of 42 nt adding the 
spacer (22 nt for target-binding) and part of the repeat sequence (reverse complement 
orientation). A 71 (bp PCR product was generated following these conditions: 3 min at 
95°C, 35 cycles of 30s at 95°C, 30s at 51°C, and 30s at 72°C, and a final step at 72 °C 
for 7 min. PCR products were purified using Favorprep Gel/PCR purification kit 
(Favorgen) columns or PCR purification kit (QIAgene) and used as template (300-500 
ng) for a T7 in vitro transcription reaction (AmpliScribe-T7-Flash transcription kit from 
Epicenter; 12-16 h of reaction). In vitro transcribed gRNAs were DNAse-treated using 
TURBO-DNAse for 15 min at 37°C and precipitated with Sodium Acetate/Ethanol. 
gRNAs were visualized in a 2% agarose stained by ethidium bromide to check for RNA 
integrity and quantify using Qubit™ RNA BR Assay Kit (ThermoFisher, Q10210). 
gRNAs targeting tbxta and tyr CDS in zebrafish and rx3 in medaka were in vitro 
transcribed from PCR containing a pool of different gRNA primers at equal 
concentration. All other gRNAs were individually in vitro transcribed and mix at equal 
concentrations in pools after the in vitro transcription. To increase mRNA depletion 3-4 
gRNAs targeting the same mRNA were co-injected, otherwise is specified in figure 
legends. 
Human codon-optimized RfxCas13d or NLS-RfxCas13d-NLS were PCR-
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amplified using primers Rfx13d_Fw and Rfx13d_Rv and Rfx13d-NLS_Fw and Rfx13d-
NLS_Rv, respectively (Table S1) and using addgene plasmid # 109049 (a gift from 
Patrick Hsu) as template (Konermann et al., 2018). The following PCR products were 
then digested with NcoI and SacII and ligated into the pT3TS-nCas9n (Jao et al., 2013) 
plasmid previously digested with the same enzymes. Human codon-optimized 
PspCas13b and PguCas13b inserts were PCR-amplified from addgene plasmids 
#103862 and #103861 (a gift from Feng Zhang) (Cox et al., 2017) using primers 
PspCas13b_FW/RV (Table S1) and PguCas13b_FW/FR, respectively ( Table S1). Both 
Cas13 PCR amplicons were subsequently digested using EcoRI-and NotI, then were 
cloned into vector pSP64T (Moreno-Mateos et al., 2017), which was previously digested 
with the same restriction enzymes. LwaCas13a-msfGFP, without and with NLS, was 
amplified from addgene plasmid #91902 (a gift from Feng Zhang) using primers 
Cas13aORF_Fw and Cas13aORF_Rv or Cas13aORF-NLS_Rv (Table S1), 
respectively. Both Cas13 PCR amplicons were subsequently digested using EcoRI-and 
XhoI, then were cloned into vector pSP64T. tbxta ORF (sense and antisense) was PCR 
amplified (Table S1). PCR products were digested with EcoRI and cloned into pSP64T 
previously digested with the same enzyme. p515-Tol2-attP-Ubi-RFP expression vector 
(see below RFP transgenic zebrafish section) was built by first cloning tag-RFP from 
p514-Ubi-TagRFP (a gift from Daniel Cifuentes of Boston University School of 
Medicine) into p328-attB-ubi:EGFP (gifted from the Piotrowski Lab at Stowers Institute) 
(Mosimann et al., 2011) via NEBuilder HiFi assembly kit (NEB) using PCR products 
from p328 plasmid amplified with pDest-gibson_FW/RV primers (Table S1) and from 
p514 plasmid amplified with tagRFP-Ubi_FW/RV (Table S1). Next the subsequent 
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construct was digested using KpnI and NotI. Plasmid p511-Tol2-attP-Tol2, purchased 
from GENEWIZ (Kwan et al., 2007), was digested using the same enzymes and cloned 
into the p328 digest, resulting in the final expression plasmid used for transgenesis, 
p515-Tol2-attP-Ubi-RFP. All final constructs were confirmed by Sanger sequencing 
(Data S1). 
To generate tbxta, RfxCas13d mRNA and LwaCas13a-GFP the DNA templates 
were linearized using XbaI and with SmaI, SacI to produce PspCas13b, PguCas13b, 
respectively. mRNA was synthesized using the mMachine T3 (Cas13d) or SP6 
(Cas13b, tbxta and Cas13a) kit (Ambion). In vitro transcribed mRNAs were DNAse-
treated using TURBO-DNAse for 15 min at 37°C and purified using the RNeasy Mini Kit 
(Qiagen) and quantifed using Qubit™ RNA BR Assay Kit (ThermoFisher, Q10210).  
Western blot 
Ten embryos were collected at 6 hours post injection and transferred to 200 µl of 
deyolking buffer for washing (55 mM NaCl, 1.8 mM KCl, and 1.25 mM NaHCO3). 
Deyolking buffer was discarded and 200 µl of the same buffer were added to resuspend 
the embryos by pipetting. The resuspended embryos were incubated at room 
temperature for 5 min with orbital shaking, and then centrifuged at 300 g for 30 s and 
washed with 110 mM NaCl, 3.5 mM KCl, 10 mM Tris-HCl pH 7.4, and 2.7 mM CaCl. 
The pellet was resuspended in SDS-PAGE sample buffer before separation by SDS-
PAGE and transferred to nitrocellulose membrane. Anti-HA antibody (11867423001, 
Roche) was used according to the manufacturer’s instructions. Secondary anti-mouse 
antibody (A5278, Sigma-Aldrich) was HRP-labelled and used according to the 
manufacturer’s instructions. Protein bands were visualised by triggering the HRP-
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catalysed chemiluminescent reaction catalysed through addition of the "Clarity" (TM) 
Western ECL Substrate (BioRad) following the manufacturer's instructions, and 
recording the chemiluminescent images in a "ChemiDoc" (TM) MP Imaging System 
(BioRad). To verify the transfer of proteins to the membrane stain-free technology (Bio-
Rad) was used. 
Zebrafish maintenance and image acquisition  
All experiments involving zebrafish at CABD conform national and European 
Community standards for the use of animals in experimentation and were approved by 
the Ethical committees from the University Pablo de Olavide, CSIC and the Andalucian 
Government. Zebrafish wild type strains AB/Tübingen (AB/Tu)  were maintained and 
bred under standard conditions (Westerfield, 1995). Wild-type zebrafish embryos were 
obtained through natural mating of AB/Tu zebrafish of mixed ages (5–18 months). 
Selection of mating pairs was random from a pool of 20 males and 20 females. 
Zebrafish embryos were staged in hours post-fertilization (hpf) as described (Kimmel et 
al., 1995). Zebrafish experiments at Stowers Institute were done according to the 
IACUC approved guidelines. Zebrafish embryos collected for microinjections were 
coming from random parents (AB, TF and TLF, 6-25 months old) mating from 4 
independent strains of a colony of 500 fish. The embryos were pooled from random 24 
males and 24 females for each set of experiment.  Wild type fish lines from University of 
New Haven were maintained in accordance with OLAW and USDA research guidelines, 
under a protocol approved by the University of New Haven IACUC. Twenty couples of 
males and females (TU and AB intermixed strains, 6-18 month old) were randomly 
selected and crossed to generate embryos for experiments described herein. For each 
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set of experiments from different laboratories both controlled and test embryos after 
injections were kept in similar condition and 200-800 embryos were injected per 
experiment (depending on the need of the experiment). 
1-2 nl containing 100-300 pg of cas13(s) mRNA (Figure S1D) and 300-600 pg of 
gRNA were injected in the cell of one-cell stage embryos (see figure legends for details 
in each experiment). Phenotypes and samples were collected, analyzed and quantified 
between 6 hours and 5 days post injection depending on the experiment. Zebrafish 
embryo phenotypes and fluorescent pictures were analysed using an Olympus SZX16 
stereoscope and photographed with a Nikon DS-F13 digital camera and images 
processed with NIS-Elements D 4.60.00 software or were imaged using Zeiss SteREO 
Lumar.V12 and Leica MZ APO stereomicroscopes. 
Transgenic RFP zebrafish: 
Transgenic zebrafish were kept according to the National Research Council’s 
and IACUC approved protocol 2016-1059 at the Stowers Institute for Medical Research 
zebrafish facility. Wild-type embryos obtained from breeding of adult AB-TU and TL-TLF 
strains were co-injected with 1 nl p515-Tol2-attP-Ubi-RFP (20 ng/ul) and capped 
transposase mRNA (50 ng/ul) (Kwan et al., 2007), at one-cell stage. Mosaic larvae 
demonstrating positive RFP fluorescence at 5 days post fertilization (dpf) were raised to 
70 dpf and outcrossed to TL-TLF wild-type fish. These embryos were screened at 5 dpf 
for ubiquitous RFP fluorescence and positive individuals were raised to use for embryo 
production. F2 embryos coming from RFP positive mothers were injected with 
RfxCas13d mRNA and RFP gRNAs.  
RNA-seq libraries and analysis: 
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mRNAseq libraries were generated from 500 ng of high-quality total RNA, as 
assessed using the Bioanalyzer (Agilent).  Libraries were made according to the 
manufacturer’s directions for the TruSeq Stranded mRNA LP Sample Prep Kit (Illumina, 
Cat. No. 20020594) with TruSeq RNA Single Indexes Set A and B (Illumina, Cat. No. 
20020492 and 20020493). Resulting short fragment libraries were checked for quality 
and quantity using the Bioanalyzer (Agilent) and Qubit Fluorometer (Life Technologies). 
Libraries were pooled, re-quantified and sequenced as 75bp single reads on a high-
output flowcell using the Illumina NextSeq instrument. Following sequencing, Illumina 
Primary Analysis version RTA 2.4.11 and bcl2fastq2 v2.18 were run to demultiplex 
reads for all libraries and generate FASTQ files.  
RNA-seq reads were aligned using STAR version 2.6.1c to Danio rerio reference 
genome danRer11 from University of California at Santa Cruz with RFP exogenmos 
sequence incorporated in its index. Transcripts were quantified using RSEM version 
1.3.0 to calculate the transcript abundance ‘TPM’ (Transcript per Million). Fold change 
for each gene was calculated using edgeR version 3.24.3 after filtering genes with a 
count of 10 reads in at least one library. The resulting p-values were adjusted with 
Benjamini-Hochberg method using R function p.adjust 
Medaka maintenance, injection and image acquisition (pics of phenotypes)   
All experiments involving medaka conform national and European Community 
standards for the use of animals in experimentation and were approved by the Ethical 
committees from the University Pablo de Olavide, CSIC and the Andalucian 
Government. The medaka wild type strain (iCab) was maintained and bred under 
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standard conditions. 15-20 couples of males and females (4 months old) were randomly 
selected and crossed to generate embryos for experiments described herein. Embryos 
were injected at single cell stage also according to standard procedures (Masato 
Kinoshita et al., 2012). Embryos were staged in hours post-fertilization (hpf) as 
described (Iwamatsu, 2004). 2 nl containing 450 pg of RfxCas13d mRNA and 1 ng of 
gRNA were injected in one-cell stage embryos. Embryos phenotype was examined and 
photographed between 30 and 72 hpf using a stereoscope (SZX16–DP71, Olympus). 
Killifish Microinjection	
Experiments at Stowers Institute were done according to the IACUC approved 
guidelines (2019-090). Random 3-to-4 months old individuals of killifish strain- inbred 
GRZ line, with opposite sex were crossed and embryos were pooled for each set of 
experiment.  Three breeding tanks were used for embryos collection. Each tank 
contained one single male and 5 female. Approximately 200 killifish embryos were 
injected at single cell stage with ~2 nl containing 200 pg of RfxCas13d mRNA and 600 
pg of gRNA. Embryos were held in 1 mm-wide trenches on a 1.5% agarose plate during 
injection. Embryos were kept in 1X Yamamoto's embryo solution with 0.0001% 
methylene blue at 28° Celsius in the darkness and fluorescent pictures were imaged 
using Leica M205 FCA stereomicroscopes. GFP and RFP fluorescence from these 
images were quantified using Fiji (Image J) software.  
Mouse embryo donors and injections 
Immature C57BL/6J female mice (3-4 weeks of age) were utilized as embryo 
donors. The C57BL/6J females were super ovulated following standard procedures with 
5 IU PMSG (Genway Biotech #GWB-2AE30A) followed 46 hours later with 5 IU hCG 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted January 14, 2020. ; https://doi.org/10.1101/2020.01.13.904763doi: bioRxiv preprint 
 24 
(Sigma #CG5) and subsequently mated to fertile C57BL/6J stud males (4-6 months of 
age).  Females were checked for the presence of a copulatory plug the following 
morning as an indication of successful mating. Out of the 20 super-ovulated females, 
approximately 10 – 12 females were plugged and harvested for embryo microinjection 
for each set of experiment. One-cell fertilized embryos were collected from the oviducts 
of mated females at 0.5 days post coitus and placed in KSOM media in a CO2 incubator 
at 37° celsius, 5% CO2 until microinjection. CRISPR-RfxCas13d reagents were 
microinjected into both the pronucleus and cytoplasm (1-2 pl total) of one-cell embryos 
using previously described techniques (Nagi et al., 2003). In brief, microinjection was 
performed using a Nikon Eclipse Ti inverted microscope equipped with Eppendorf 
TansferMan micromanipulators, Eppendorf CellTram Air® for holding of embryos, and 
Eppendorf FemtoJet® auto-injector. A small drop of M2 media was placed on a 
siliconized depression slide and approximately 20-30 C57BL/6J oocytes were 
transferred to the slide for microinjection. The slide was placed on the stage of the 
microscope and oocytes were injected at 20x. Immediately following microinjection, the 
embryos were returned to the CO2 incubator in KSOM culture media and observed 
daily for embryo development. Animals were maintained in Lab Animal Service Facility 
(LASF) of Stowers Institute at 14:10 light cycle and provided with food and water ad 
libitum. Experimental protocols were approved by the Institutional Animal Care and Use 
Committee at Stowers Institute and were in compliance with the NIH Guide for Care and 
Use of Animals. 
 For toxicity testing, embryos were injected as described above with varying 
concentrations of RfxCas13d mRNA to test for toxicity. Injections concentrations were 
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2.5 ng/ul, 10 ng/ul, 25 ng/ul and 50ng/ul. A Stock solution of RfxCas13d mRNA was 
serially diluted using Tris Low EDTA microinjection buffer. Initial observations indicated 
the embryos responded normally to the microinjection. Embryos were cultured overnight 
as described above and observed the following morning for development. Embryos 
were returned to the incubator and observed each day to track the development to the 
3.5 days post coitus blastocyst stage.  
For RfxCas13d mRNA and gRNA Injections, reagents were prepared and 
delivered on ice at the desired injection concentrations. Injections concentrations were 
RfxCas13d mRNA (25 ng/ul), gRNA RFP (100 ng/ul), GFP and RFP mRNA (8-10 ng/ul). 
Fluorescent images were taken using Nikon ECLIPSE Ti 2 microscope. 
qRT-PCR 
For checking the level of targeted mRNA in zebrafish embryos, 20 embryos per 
biological replicate were collected for all zebrafish qRT PCRs at the described hours 
post injection in figures or legends and snap frozen in liquid nitrogen. Total RNA was 
isolated using standard TRIzol protocol as described in the manual (Life technologies). 
The cDNA was synthesized using SuperCript™ IV First- Strand Synthesis System, 
following the manufacturer’s protocol. To set up the real time qPCR for different genes, 
1/25 cDNA dilution was used using forward and reverse primers per mRNA (10 µM; 
Table S1) in a 10 µl reaction. Samples were prepared as instructed for automated 
Freedom EVO® PCR workstation (Tecan) and run in QuantStudio 7 Flex Thermo cycler 
(Applied Biosystem) 
Eight medaka embryos were collected at stage 16 (21 hpf) per biological 
replicate (except for WT uninjected that 5 embryos were collected). Total RNA was 
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isolated from embryos injected using TRIzol reagent (Life Technologies). An amount of 
500-1000 ng of purified total RNA was then subjected to reverse transcription using the 
iScript cDNA synthesis kit (Bio-Rad), following the manufacturer’s protocol. 4.5 
microliters from a 1/25 dilution of the cDNA reaction was used to determine the levels of 
rx3 mRNA in a 10 µl reaction containing 0.5 µl of forward and reverse primers (10 µM 
each; Table S1), using iTaq Universal SYBR Green Supermix (Bio-Rad) and a CFX 
connect instrument (Bio-Rad). PCR cycling profile consisted in a denaturing step at 95 
°C for 30 s and 40 cycles at 95 °C for 1 s and 60 °C for 30 s. Two technical qPCR 
replicates were performed per biological replicate. 
Nano-luciferase activity:  
For nano-luciferase mRNA targeting, 10 pg of nano-luciferase mRNA and firefly 
luciferase mRNA (as an internal control) together with different experimental conditions 
including RfxCas13d (200 pg) and/or gRNA-nanoluciferase cocktail (400 pg) were 
injected per zebrafish embryo at one cell stage.  Injected embryos were collected at 6 
hours post injection and at least 8 tubes (5 embryos per tube) per condition were snap 
frozen in liquid nitrogen. Nano-Glo Dual-Luciferase® reporter assay protocol (Promega) 
was followed as instructed in the manual for assaying the activity of nanoluciferase and 
firefly luciferase activity using infinite M200 PRO by TECAN.  
Statistics  
No statistical methods were used to predetermine sample size. The experiments 
were not randomized, and investigators were not blinded to allocation during 
experiments and outcome assessment. No data were excluded from the analysis. 
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Unpaired two-tailed Mann–Whitney and χ2-test (chi-squared) tests were used to 
compare the results from CRISPR-RfxCas13d and Morpholino (MO) targeting nanog 
and different injections conditions, respectively. These tests were performed using R. 
For quantitative RT-PCR and luciferase activity p value was calculated using unpaired t-
test or one-way ANOVA test using Prism (GraphPad Software, La Jolla, CA, USA) and 
Standard Error of the Mean (SEM) was used to show error bars. As it was described in 
the RNA-seq section, the fold change for each gene was calculated using edgeR 
version 3.24.3 after filtering genes with a count of 10 reads in at least one library. The 
resulting p-values were adjusted with Benjamini-Hochberg method using R function p 
value adjusted using two biological replicates.  
Data availability 
Original data underlying this manuscript can be accessed from the Stowers Original 
Data Repository at http://www.stowers.org/research/publications/libpb-1454. The 
Stowers Institute contributing authors have selected to present the raw data of this 
manuscript resulting from work performed at The Stowers Institute. The RNA-seq data 
have been deposited in GEO under accession code GSE135884. All the mRNA level 
measure by RNA-seq are provided in Table S2.  
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Legends 
Figure 1. CRISPR-RfxCas13d system targeting tbxta recapitulates no-tail 
phenotype in zebrafish embryos. A) Schematic illustration of the experimental set-up 
used to analyze CRISPR-Cas13 toxicity. 200 pg of mRNA from each Cas13 variant was 
injected into one-cell stage zebrafish embryos. Cas13b and Cas13d are tagged with HA 
and Cas13a is fused to GFP. B) Toxicity evaluation of embryos. Stacked barplots 
showing the percentage of deformed and wild type (WT) zebrafish embryos (30 hours 
post fertilization, hpf) injected in conditions described in a. Number of embryos 
evaluated (n) is shown for each condition. C) Schematic of positions of six gRNAs (red 
lines) targeting tbxta CDS in zebrafish (top). Schematic of experimental set-up to 
analyze CRISPR-RfxCas13d-mediated RNA knockdown in zebrafish (bottom). Two sets 
of gRNAs targeting tbxta CDS (1-3 or 4-6; 300 pg per embryo) were mixed with mRNA 
(100 or 200 pg per embryo) coding for RfxCas13d and injected into one-cell stage 
embryos. D) Phenotypic severity in embryos injected with RfxCas13d mRNA (mCas13d) 
and gRNAs targeting tbxta (gNTL) compared to uninjected wild type (WT) evaluated at 
30 hours post fertilization (hpf) (scale bar, 0.5 mm). Class I: Short tail (least extreme). 
Class II: Absence of notochord and short tail (medium level). Class III: Absence of 
notochord and extremely short tail (most extreme). E) Different gNTL sets recapitulate 
no-tail phenotype. Stacked barplots showing percentage of observed phenotypes under 
various injection conditions. Number of embryos evaluated (n) is shown for each 
condition. F) no-tail phenotype can be rescued. Stacked barplots showing percentage of 
observed phenotypes using gNTLs targeting 3’UTR (300 pg/ embryo) and mCas13d 
(200 pg/embryo) co-injected with different mRNAs: GFP (mGFP ORF, 100 pg/embryo), 
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tbxta ORF with 3’UTR from pSP64T plasmid (mNTL CDS, 100 pg/embryo), or tbxta 
antisense (mNTL anti-se, 100 pg/ embryo) ORF. As an additional control, an unrelated 
gRNA set targeting a gene involved in germ cell formation (dnd1) was included (300 
pg/embryo). Number of embryos evaluated (n) is shown for each condition. G) qRT–
PCR analysis showing levels of tbxta mRNA at 7 hours post injection (hpi) in conditions 
described in panel c. Results are shown as the averages ± standard error of the mean 
from 2 independent experiments with 1 (mCas13d alone) or 2 biological replicates per 
experiment (n=20 embryos/ biological replicate) or Cas13 and Cas13 plus gNTL, 
respectively). p value of 0.0092 (t-test). cdk2ap mRNA was used as normalization 
control.  
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Figure 2. CRISPR-RfxCas13d specifically targets reporter mRNAs in zebrafish 
embryos. Schematics of A) rfp and gfp mRNAs or B) Nano-luciferase and Firefly 
mRNAs (10 pg/embryo) co-injected with/without RfxCas13d mRNA (200 pg/embryo) 
and/or gRNAs (250-400 pg/embryo) targeting rfp or Nano-Luciferase mRNA, 
respectively. C) Fluorescence images of representative embryos at 6 hpi with indicated 
mRNAs and gRNAs (scale bar, 0.5 mm). D) Ratio of nanoluciferase activity normalized 
to firefly luciferase activities under indicated conditions at 6 hpi. Results are shown as 
the averages ± standard error of the mean from at least 4 biological replicates per 
experiment (n=5 embryos/ biological replicate). p value < 0.0001, mCas13 and gNano-
Luc compared to other conditions (one-way ANOVA). E) qRT-PCR analysis of ratio of 
RFP reporter mRNAs under indicated conditions at 6 hpi normalized with GFP mRNA. 
Results are shown as the averages ± standard error of the mean from 2 independent 
experiments with at least 2 biological replicates per experiment (n=20 embryos/ 
biological replicate). p value < 0.0001, mCas13 and gRFP compared to other conditions 
(one-way ANOVA).  F) Nanoluciferase mRNA level normalized to firefly mRNA level at 6 
hpi at indicated conditions. Results are shown as the averages ± standard error of the 
mean from 2 independent experiments with 2 biological replicates per experiment (n=20 
embryos/ biological replicate). p value < 0.05, mCas13 and gNano-Luc compared to 
mCas13d alone or mNano-Luc and mFirefly alone (one-way ANOVA) G) Schematic of 
mRNAs (RfxCas13d and gfp) and gRNAs targeting rfp introduced into embryos derived 
from transgenic mother expressing rfp. Fluorescence images of representative embryos 
at 26 hpi with indicated mRNAs and/or gRNAs. H) Fluorescence images of 
representative embryos at 26 hpi injected with indicated mRNAs and/or gRNAs (scale 
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bar, 0.5 mm). I) Scatter plot showing mRNA level (RNA-seq) of zebrafish embryos at 6 
hpi. Left panel, mRNA level of uninjected embryos versus embryos injected with 
RfxCas13d mRNA alone. Right panel, mRNA level of embryos injected with RfxCas13d 
mRNA plus rfp gRNAs versus embryos injected with RfxCas13d mRNA alone. rfp 
mRNA is indicated in red. Dashed lines indicate a 4-fold difference between RNA levels.  
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Figure 3. CRISPR-RfxCas13d recapitulates known loss-of-function zebrafish 
phenotypes. A) Schematic of RfxCas13d mRNA (200-250 pg/embryo) and gfp mRNA 
containing the 3’UTR of nanos (40 pg/embryo) co-injected with/without gRNAs targeting 
dnd1 (500-600 pg/embryo) or tyr (500-600 pg/embryo).  Germ cells are highlighted by 
germ-cell specific fluorescence (due to nanos-3’UTR) at 30 hpf. The ratio of embryos 
displaying intact germ cells (mCas13d alone or mCas13d plus gTyr) or without germ 
cells (mCas13d plus gDND1) vs total number of analyzed embryos (at least from two 
independent experiments) are indicated (scale bar, 0.5 mm). B) Scatter plot showing 
mRNA level (RNA-seq) of zebrafish embryos injected with RfxCas13d mRNA (250 
pg/embryo) alone versus RfxCas13d mRNA plus dnd1 gRNAs (600 pg/embryo) after 6 
hpi, dnd1 mRNA is indicated in red (~8-fold change). Dashed lines indicate a 4-fold 
difference between RNA levels. C) Pigmentation phenotypes (52 hpf) of head/eyes of 
embryos injected with RfxCas13d mRNA alone (300 pg/embryo, left), tyr gRNAs alone 
(600 pg/embryo, center), or both (right) (scale bars, 0.5 mm). The ratios of embryos 
displaying intact pigmentation (mCas13d or gTyr alone) or with the lack of pigmentation 
(mCas13d plus gTyr) vs total number of analyzed embryos are indicated. D) 
Representative pictures of epiboly-stage zebrafish embryos displaying gastrulation and 
epiboly defects in embryos injected with RfxCas13d mRNA plus nanog gRNAs 
(gNanog), but not in embryos injected with either RfxCas13d mRNA alone or 
RfxCas13d mRNA plus gfp gRNAs (gGFP). The ratios of embryos displaying normal 
development (RfxCas13d mRNA alone or RfxCas13d mRNA plus gGFP) or with epiboly 
and gastrulation defects  (RfxCas13d mRNA plus gNanog) vs total number of analyzed 
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embryos are indicated. Embryos were injected with 250 pg, 430 pg and 600 pg of 
mCas13d, gGFP and gNanog, respectively (scale bar, 0.1 mm). E) Scatter plot showing 
mRNA level (RNA-seq) of zebrafish embryos injected with RfxCas13d mRNA plus 
nanog gRNAs compare to embryos injected with RfxCas13d mRNA alone at 6 hpi. 
nanog mRNA is indicated in red. Black outline indicates genes that display reduced 
expression (>4-fold decrease) in nanog morhpholino-treated (MO) embryos. Dashed 
lines indicate a 4-fold difference between RNA levels. 
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Figure 4. CRISPR-RfxCas13d as RNA targeting tool in different animal models. A) 
Representative pictures of medaka embryos at 68 hpf showing arrested eye 
development in embryos injected with RfxCas13d mRNA (450 pg) with gRNAs (1 ng) 
targeting rx3 mRNA (gRX3) compared to the embryos injected with RfxCas13d mRNA 
alone or uninjected embryos. Double arrows and asterisk indicate eye length and 
absence of eye, respectively (scale bar, 0.1mm). B) Fluorescence microscopy images 
of killifish embryos showing RFP and GFP intensity of uninjected embryos or after 14 
hpi injected with rfp and gfp mRNAs, with or without RfxCas13d mRNA (250-350 
pg/embryo) and/or gRNAs (300 – 400 pg/embryo) targeting rfp mRNA (scale bar, 0.1 
mm). C) Fluorescence microscopy images of mouse embryos 24 hours post injection (2 
cell-stage) with rfp and gfp mRNAs with or without RfxCas13d mRNA and/or gRNAs 
targeting rfp or unrelated (zebrafish tyr) mRNA (scale bar, 100 um).  D) Stacked plots 
showing the percentage of mouse embryos at 1 or 2 cells stage 24 hours post injection 
with the indicated mRNA and/or gRNAS. The number of embryos (n) is indicated from 
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Supplementary figure 1. CRISPR-Cas13 optimization in zebrafish 
A) Western-blot for HA showing protein level at 6 hpi of the indicated Cas13 after 
injection of the encoding mRNA for each respective Cas13 mRNA into single cell 
zebrafish embryos. B) Representative pictures of embryos at 4.5 hours post fertilization 
(hpf) uninjected or injected with 200 pg of mRNA encoding for Lwa-Cas13a-GFP or 
GFP (scale bar, 0.1 mm). Lack of GFP expression was also observed using Cas13a-
NLS-GFP version (not shown). C) Representative pictures of zebrafish embryos at 30 
(top) or 26 (bottom) hpf uninjected or injected with 200 pg of mRNA encoding for 
RfxCas13d, PguCas13b or PspCas13b (scale bar, 1 mm).D) Toxicity evaluation of 
embryos. Stacked barplots showing the percentage of deformed and wild type (WT) 
zebrafish embryos (30 hpf) injected with different concentrations of RfxCas13d mRNA. 
Number of embryos evaluated (n) is shown for each condition. E) Schematic of gRNA 
structure for RfxCas13d (top) and scheme showing a gRNA (binding sequence in red, 
direct repeat in blue) binding to the mRNA (black). Adapted from Moreno-Mateos et al 
201730. F) Diagram of the gRNA generation by fill-in PCR followed by in vitro 
transcription. An oligonucleotide containing the T7 promoter (green) followed by two 
Guanine and 30 nt of the direct repeat (in blue) for annealing is used in combination 
with oligonucleotide containing 20 nt of the reverse complement of the repeat and 22 nt 
of the binding sequence (in red). Adapted from Moreno-Mateos et al 201734. G) 
Representative pictures of zebrafish embryos at 32 hpf injected with gRNAs targeting 
tbxta (gNTL 4-6; 300 pg/embryo) and/or RfxCas13d mRNA (200 pg/embryo) (scale bar, 
1 mm). H) Stacked barplots showing percentage of observed phenotypes using gNTLs 
targeting CDS (gNTLS 4-6, 300 pg/embryo) co-injected with RfxCas13d mRNA without 
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(mCas13d) or with C- and N-terminal nuclear localization sites (mCAS13d-NLS) (200 
pg/embryo each mRNA). Knockdown classes are described in Figure 1D. Number of 
embryos evaluated (n) is shown for each condition. I) Pictures of representative 
embryos injected with the indicated mRNA and/or gRNAs described in (scale bar, 0.1 
mm) Figure1F. 
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Supplementary figure 2. CRISPR-RfxCas13d system efficiently targets reporter 
mRNAs in zebrafish. A) Fluorescence microscopy images of zebrafish embryos at 6 
hours post injection with the indicated mRNA and gRNAs (scale bar, 0.5 mm).  B) 
Relative level of firefly luciferase activity at 6 hours from the firefly luciferase mRNA 
injected as an internal control for each combination described in Figure 2D. C) 
Fluorescence microscopy images showing the RFP intensity in gRNA targeted RFP in 
transgenic fish at 3.5 and D) 5 days post injection using the indicated mRNA and/or 
gRNAs, suggesting time dependent recovery of RFP expression (scale bar, 0.1 mm).  
E) qRT–PCR analysis showing levels of rfp mRNA at 6 hpi in transgenic embryos 
injected with RfxCas13d mRNA alone or together with gRNAs targeting dnd1 or rfp 
mRNAs. Results are shown as the averages ± standard error of the mean from 2 
independent experiments (n=20 embryos / experiment). Taf15 mRNA was used as 
normalization control. F) Scatter plots representing the fold change in mRNA and the 
associated P value from two biological RNA-seq replicates at 6 hours post injection with 
the indicated gRNAs and/or mRNA encoding for RfxCas13d in RFP transgenic 
embryos. rfp mRNA is indicated in Red.   
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Supplementary figure 3. CRISPR-RfxCas13d system efficiently targets 
endogenous mRNAs in zebrafish. A) qRT–PCR analysis showing levels of dnd1 
mRNA in embryos at 6 hpi injected with RfxCas13d mRNA alone or together with 
gRNAs targeting dnd1 mRNA. Results are shown as the averages ± standard error of 
the mean from 2 independent experiments with 2 biological replicates per experiment 
(n=20 embryos/ biological replicate). Taf15 mRNA was used as normalization control (P 
value=0.0099, t-test). B) Scatter plots representing the fold change in mRNA and the 
associated P value from two biological RNA-seq replicates at 6 hours post injection with 
gRNAs targeting dnd1 and/or mRNA encoding for RfxCas13d. dnd1 mRNA is indicated 
in Red. C) Representative pictures of zebrafish embryos from the experiment described 
in Figure 3C (scale bar, 1 mm). D) Representative pictures of embryos injected with 
gRNAs targeting nanog CDS (225 pg per embryo injected at one-cell stage, gNanog) 
and/or mRNA (100 or 200 pg per embryo injected at one-cell stage) coding for 
RfxCas13d (Cas13d) showing different developmental stages. Shield, germ ring and 
50% epiboly (50% epi) correspond to 6, 5.7 and 5.3 hpf in wild type embryos growing in 
standard conditions, respectively (scale bar, 0.1 mm.) E) Stacked barplots showing 
percentage of observed phenotypes under conditions described in panel e. Number of 
embryos evaluated (n) is shown for each condition. F) qRT–PCR analysis showing 
levels of nanog mRNA in embryos at 6 hpi injected with RfxCas13d mRNA alone or 
together with gRNAs targeting nanog mRNA (P value < 0.0001, t-test). Results are 
shown as the averages ± standard error of the mean 2 independent experiments with at 
least 2 biological replicates each (n=20 embryos/ biological replicate).  Taf15 mRNA 
was used as normalization control. G) Scatter plots representing the fold change in 
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mRNA and the associated P value from two biological RNA-seq replicates at 6 hours 
post injection with gRNAs targeting nanog and/or mRNA encoding for RfxCas13d. 
nanog mRNA is indicated in Red. Dashed lines indicate more than 4-fold differences 
between in RNA level and P adjusted value = 1e4). Black outline indicates mRNA that 
display reduced expression (>4-fold decrease and < P adjusted value = 1e4) due to the 
injection of RfxCas13d with gRNAs targeting nanog. H) Boxplot showing that the 
mRNAs down regulated in the embryos injected with RfxCas13d with gRNAs targeting 
nanog (Black outline in panel g) also display lower mRNA level in embryos injected with 
morpholino targeting nanog expression compare to uninjected embryos (P value < 4.4e-
11, Mann–Whitney U-test). The box defines the first and third quartiles, with the median 
indicated with a thick black line and vertical lines indicate the variability outside the 
upper and lower quartiles. i) The percentage of mRNA reduction due to CRISPR-
RfxCas13d for each targeted mRNA measured by RNA-seq (square) or q-RT-PCR 
(circles). Dashed line indicates the median of all the mRNA knock-downs. 
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Supplementary figure 4. CRISPR-RfxCas13d targets different mRNAs in animal 
models. A) qRT–PCR analysis showing levels of rx3 mRNA in medaka embryos at 21 
hpf injected with RfxCas13d mRNA alone or together with gRNAs targeting rx3 mRNA. 
Results are shown as the averages ± standard error of the mean from 2 (uninjected 
embryos) or 3 biological replicates (two technical replicates per biological replicate). 
actin-beta mRNA was used as normalization control. The data were subjected to one-
way ANOVA test. B) Representative pictures of medaka embryos at 30 hpf injected in 
the conditions described in Figure 4A and showing different grade of severity of the 
phenotype. Double arrows and asterisk indicate eye length and absence of eye, 
respectively (scale bar, 0.1 mm). C) Stacked barplots showing percentage of observed 
medaka phenotypes at 30 hpf (panel a) under injection conditions described in Figure 
4A. Number of embryos evaluated (n) is shown for each condition. D) qRT–PCR 
showing levels of RFP mRNA reduction with respect to mGFP in Killifish embryos 
injected with RFP, GFP and RfxCas13d mRNA with or without gRNAs targeting RFP 
mRNA. Results are shown as the averages ± standard error of the mean from 2 
biological replicates (P= 0.0081, t-test) (n=20 embryos/biological replicate) E) Box plot 
showing the logarithmic ratio between the RFP and GFP fluorescence intensity 
observed in killifish embryos after 14 hpi with the indicated mRNA and/or gRNAs from at 
least 9 embryos per condition. The RFP/GFP intensity ratio was compared between 
mRFP-mGFP condition (without CRISPR-RfxCas13d) vs mCas13d alone, gRFP alone 
and mCas13d plus gRFP, (P< 0.0001, P=0.1366 and  P= 0.0216, respectively; one-way 
ANOVA). The box defines the first and third quartiles, with the median indicated with a 
thick black line and vertical lines indicate the variability outside the upper and lower 
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quartiles. F) Stacked plots showing the percentage of mouse embryos at 1 or 2 cells 
stage or lysed after 24 hours post injection with 1-2 ul of the indicated RfxCas13d 
mRNA concentration. The number of embryos (n) is indicated for each condition. G) Bar 
plot showing the proportion of embryos injected with different RfxCas13d mRNA 
concentration that reach Morula stage. The number of embryos (n) is indicated for each 
condition. 
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